Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PAR
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world. In 2023 alone, it is estimated that 288,300 US men will be diagnosed with prostate cancer and 34,700 will die from the disease despite the approval of multiple systemic agents. Due to advances in screening and imaging technol
| Condition(s) | Prostate Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world. In 2023 alone, it is estimated that 288,300 US men will be diagnosed with prostate cancer and 34,700 will die from the disease despite the approval of multiple systemic agents. Due to advances in screening and imaging technology, PCa is now detected much earlier in its disease course. Prostate gland ablation for prostate cancer might provide the option for a "middle" ground between active surveillance (AS) and radical therapy by destroying prostate cancer in a minimally invasive or non-invasive fashion and thus limiting the morbidity. This treatment strategy is increasingly being offered to patients due to low morbidity but the data on long term oncologic efficacy and side effect profile is lacki |
| Who can participate | Inclusion Criteria: * Male sex * ≥22 years of age * Histologic diagnosis of prostate cancer * Scheduled to undergo or have already undergone ablation of the prostate as part of routine clinical care or any ongoing clinical trials * Prostate ablation performed with any of the following energy sources: cryotherapy, high-intensity focused ultrasound, irreversible electroporation, laser, microwave, radiofrequency ablation, or photodynamic therapy. Newer methods and instrumentation continue to be developed to ablate tissue, and these energy sources can be entered into the registry as clinical use begins Exclusion Criteria: * Under 21 Years of age. |
| Ages | 22 Years |
| Sex | Male |
| Lead sponsor | University of Chicago |
| Locations | Hyde Park, Illinois, United States; Cincinnati, Ohio, United States |
| Start date | 2024-06-21 |
| NCT ID | NCT06705803 |
| Official listing | https://clinicaltrials.gov/study/NCT06705803 |